170353-28-3

Basic information

• Product Name: [1-(Pyridin-2-yl)piperidin-4-yl]methanamine
• Synonyms: [1-(Pyridin-2-yl)piperidin-4-yl]methanamine;[(1-Pyridin-2-ylpiperidin-4-yl)methyl]amine
• CAS NO: 170353-28-3
• Molecular Formula: C₁₁H₁₇N₃
• Molecular Weight: 191.27278
• Mol File: 170353-28-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1-(Pyridin-2-yl)piperidin-4-yl]methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(Pyridin-2-yl)piperidin-4-yl]methanamine(170353-28-3)
• EPA Substance Registry System: [1-(Pyridin-2-yl)piperidin-4-yl]methanamine(170353-28-3)

Safety Data

• Hazardous Substances Data: 170353-28-3(Hazardous Substances Data)

Usage

General Description

[1-(Pyridin-2-yl)piperidin-4-yl]methanamine, also known as 1-(2-pyridyl)-4-(4-piperidinyl) methanamine, is a chemical compound that belongs to a class of organic compounds known as piperidines. It is a derivative of piperidine, a heterocyclic amine with a six-membered ring containing five carbon atoms and one nitrogen atom. [1-(Pyridin-2-yl)piperidin-4-yl]methanamine is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its unique structure and properties. It has shown potential as a ligand in the development of new drugs and as a building block in organic synthesis. Its chemical structure and reactivity make it a valuable tool in medicinal and chemical research.

Upstream product

• 109-09-1 2-chloropyridine 
• 7144-05-0 4-Aminomethylpiperidine 
• 302341-46-4 benzyl ((1-(pyridin-2-yl)piperidin-4-yl)methyl)carbamate 
• 123-51-3 i-Amyl alcohol 
• 132431-09-5 benzyl (piperidin-4-ylmethyl)carbamate 
• 372-48-5 2-fluoropyridine 

Relevant articles and documents

SMARCA INHIBITORS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are useful in treatment of cancer.

Integrin receptors antagonists

The invention relates to novel compounds which bind to integrin receptors, and to the preparation thereof and the use thereof as drugs.

Bicyclic aromatic compounds as therapeutic agents

Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which A is methylene or --O--; B is methylene or --O--; and g is 0, 1, 2, 3 or 4; R1, R2, R3, R4, U, Q and T are defined in claim 1. The compounds have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.